CM
ASMB icon

Caption Management’s Assembly Biosciences ASMB Stock Holding History

Caption Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-18,750
Closed -$783K – 1577
2021
Q3 		$783K Sell
18,750
-2,083
-10% -$87.3K 0.01% 1094
2021
Q2 		$970K Buy
+20,833
New +$1.03M 0.01% 902

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Caption Management's ASMB Position: Q2 2026 in Review

Caption Management reduced its Assembly Biosciences (ASMB) stake by 72% in Q2 2026, selling an estimated $1.61M and leaving 22,829 shares worth $627K. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

Caption Management first reported a position in ASMB in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.63M in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Caption Management held 22,829 shares of Assembly Biosciences worth $627K as of Q2 2026.
  • Caption Management sold 59,012 Assembly Biosciences shares in Q2 2026, an estimated $1.61M.
  • Assembly Biosciences made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1266 holding.
  • Caption Management first reported a position in Assembly Biosciences in Q2 2019 and has held it in 9 quarters since.
  • Caption Management's Assembly Biosciences position peaked at $3.63M in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.